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ABSTRACT
Objective Extended walking speed is a predictor of
incident cardiovascular disease (CVD) in older individuals,
but the ability of an objective short-distance walking
speed test to stratify the severity of preclinical conditions
remains unclear. This study examined whether
performance in an 8-ft walking speed test is associated
with metabolic risk factors and subclinical
atherosclerosis.
Design Cross-sectional.
Setting Epidemiological cohort.
Participants 530 adults (aged 6366 years, 50.3%
male) from the Whitehall II cohort study with no known
history or objective signs of CVD.
Main outcome Electron beam computed tomography
and ultrasound was used to assess the presence and
extent of coronary artery calciﬁcation (CAC) and carotid
intima-media thickness (IMT), respectively.
Results High levels of CAC (Agatston score >100) were
detected in 24% of the sample; the mean IMT was
0.75 mm (SD 0.15). Participants with no detectable CAC
completed the walking course 0.16 s (95% CI 0.04 to
0.28) faster than those with CAC $400. Objectively
assessed, but not self-reported, faster walking speed
was associated with a lower risk of high CAC (odds ratio
0.62, 95% CI 0.40 to 0.96) and lower IMT (b¼ 0.04,
95% CI  0.01 to  0.07 mm) in comparison with the
slowest walkers (bottom third), after adjusting for
conventional risk factors. Faster walking speed was also
associated with lower adiposity, C-reactive protein and
low-density lipoprotein cholesterol.
Conclusions Short-distance walking speed is
associated with metabolic risk and subclinical
atherosclerosis in older adults without overt CVD. These
data suggest that a non-aerobically challenging walking
test reﬂects the presence of underlying vascular disease.
Performance on extended walking tests predicts
total mortality and incident cardiovascular disease
(CVD) in older individuals,
1 but the ability of short-
distance walking speed to stratify the severity of
subclinical CVD remains uncertain. Several non-
invasive imaging techniques can be employed to
examine the extent of subclinical atherosclerosis,
23
which precedes CVD. In a study of 387 healthy,
older participants from the Cardiovascular Health
Study, coronary artery calciﬁcation (CAC) was
inversely related to objectively measured walking
speed in women but such an association was not
seen in men.
4 In the Three-City study, carotid
intima-media thickness (IMT), another proxy
measure of subclinical atherosclerosis, was inversely
associated with objectively measured maximum
walking speed.
5 In the Multi-Ethnic Study of
Atherosclerosis self-reported brisk walking pace was
associated with lower CAC and IMT in men but
only IMT in women.
6
Short-distance tests of walking speed compared
with those of long-distance and maximum walking
speed have several advantages. They can be
performed using relatively little clinic space, they
are particularly safe and easy to administer, and are
not aerobically demanding for the participant. We
are not aware of any large-scale studies that have
examined the ability of a short-distance walking
speed test to capture variation in multiple markers
of preclinical atherosclerosis. The aim of the
present study was therefore to examine whether
the performance in an 8-ft walking speed test is
associated with metabolic risk factors and subclin-
ical atherosclerosis, assessed from both CAC and
carotid IMTamong older men and women with no
overt CVD. A second aim was to compare the
predictive utility of the objective walking test with
that of self-reported walking pace.
METHODS
Participants
A subsample of participants from phase 7 (2003e4)
of the Whitehall II epidemiological cohort
7 were
recruited for the assessment of CAC in 2006e8. The
inclusion criteria for the study were no history or
objective signs of coronary heart disease, veriﬁed by
clinical examination including ECG, and no
previous diagnosis or treatment for hypertension or
diabetes, inﬂammatory diseases (including
arthritis), or allergies. Thirteen participants (2.4%)
were prescribed lipid-lowering medication (statins).
Volunteers were of white European origin, aged
53e76 years, and 56.5% were in full-time employ-
ment. Selection was stratiﬁed by grade of employ-
ment (current or most recent) to include higher and
lower socioeconomic status participants. From the
initially invited 1169 participants, 323 (27.6%) were
not eligible (mainly because of prescribed antihy-
pertensive medications) and 303 (25.9%) declined to
take part. A higher proportion of participants from
lower work grades declined to take part compared
with higher grades, (38.6% vs 20.3%, respectively).
Participants were prohibited from using any anti-
histamine or anti-inﬂammatory medication 7 days
before testing, and were rescheduled if they reported
colds or other infections on the day of testing.
Participants gave full informed consent to partici-
pate in the study and ethical approval was obtained
from the UCLH committee on the ethics of human
research.
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EpidemiologyClinical assessment
Details of the Whitehall II phase 7 clinical assessment are
published elsewhere.
7 Walking speed was measured by a trained
nurse over a clearly marked 8-ft walking course using a stand-
ardised protocol.
8 Participants wore either low-heeled close-
ﬁtting footwear or walked barefoot. Before the test, participants
were shown the walking course and asked to ‘walk to the other
end of the course at your usual walking pace, just as if you were
walking down the street to go the shops. Walk all the way past
the other end of the tape before you stop.’ The starting position
was standing with both feet together at the start of the course.
Participants were asked to begin walking when properly posi-
tioned. The stopwatch was started as the participant’s foot hit
the ﬂoor across the starting line. Nurses walkedbehind and to the
side of the participant and stopped timing when the participant’s
foot hit the ﬂoor after the end of the walking course. The test
was repeated three times, and performance time on the last walk
was used for the present analyses. We also calculated coefﬁcient
of variation of the three walks for each participant. Participants
reported habitual physical activity from a 20-item question-
naire,
9 a question about usual walking pace (slow/average/brisk/
fast), current smoking levels, weekly alcohol intake (units per
week) and self-rated health (excellent/very good/good/fair/poor).
The physical function scale from the medical outcomes study
short-form 36 health survey (SF-36) was used to assess activities
of daily living.
10 Respondents were asked about limitations to
everyday activities such as lifting, climbing stairs and walking.
Scores can range from 0 to 100, with lower scores indicating
greater impairment. Anthropometric measures were recorded in
light clothing for the calculation of body mass index (BMI), and
body fat percentage was measured using a bio-impedance device
(BodyStat 1500 Medical, UK). Fasting venous blood samples
were taken for the analysis of C-reactive protein (CRP), which
was performed using high-sensitivity ELISA (R&D Systems,
Oxford, UK), and total and high-density lipoprotein (HDL)
cholesterol and triglycerides, which were measured within 72 h
in serum stored at 48C using enzymatic colorimetric methods.
Low-density lipoprotein (LDL) cholesterol was derived using the
Friedewald equation. Glucose homeostasis was assessed from
fasting glucose.
Markers of subclinical atherosclerosis
The assessment of CAC was performed using electron beam
computed tomography (GE Imatron C-150; San Francisco,
California, USA) as previously described.
11 In brief, 40 contig-
uous 3-mm slices were obtained during a single breath-hold
starting at the carina and proceeding to the level of the dia-
phragm. Scan time was 100 ms/slice, synchronised to 40% of the
R-R interval. Agatston and volumetric calcium scores were
calculated to quantify the extent of CAC by a single experienced
investigator blinded to the clinical data on an Aquarius work-
station (TeraRecon Inc, San Mateo, California, USA). Carotid
IMT was measured using ultrasound scanning.
3 The right and
left common carotid arteries were scanned with a 5e10-MHz
probe (Alokia Prosound 2000, Tokyo, Japan). The carotid bulb
was identiﬁed, and longitudinal two-dimensional ultrasono-
graphic images of the common carotid artery 1e2 cm proximal
to the carotid bulb were obtained. The optimal longitudinal
image was acquired on the R-wave of the ECG and continuously
recorded on video tape for 5 s. Measurements of the posterior
wall of the artery were made from stored images with electronic
calipers. Carotid IMTwas calculated as the distance between the
ﬁrst bright light (lumeneintima interface) and the leading edge
of the second bright light (mediaeadventitia interface). The
three maximum measures from the right carotid artery in three
different frames and the three maximum measures from the left
common carotid artery in three different frames were averaged.
Statistical analysis
Thirteen participants with missing data (n¼6 walking test, n¼7
bloods) were excluded from all analyses. Walking speed was
stratiﬁed into three equal sex-speciﬁc groups, denoting fast
(<1.73 s), medium (women, 1.73e2.10 s; men, 1.73e1.94 s) and
slow (women >2.10 s, men >1.94 s). Walking speed variability
was also stratiﬁed into three equal groups, denoting low (<5%),
medium (5e8%), high (>8%). Because of the skewed distribu-
tion, CAC was dichotomised and multivariate logistic regression
analyses were employed to examine the association of walking
speed and variability with the presence of high CAC (Agatston
score $100). This threshold was based on previous data that
demonstrated maximum sensitivity and speciﬁcity for detecting
cardiovascular events at a threshold calcium score of 100 or
greater.
12 We calculated odds ratios (OR) and 95% CI for the risk
of high CAC according to objectively measured and self-reported
walking speed categories, adjusting for age, sex, employment
grade (as a marker of social position), smoking, SF-36, statins and
conventional risk factors, including BMI, systolic blood pressure,
LDL and HDL cholesterol, fasting glucose and CRP. Since the
majority of participants reported ‘average’ or ‘brisk’ walking pace
we constructed two categories consisting of ‘slow/average’ and
‘brisk/fast’ pace. For consistency the objectively measured
walking speed was also split into two categories for these anal-
yses, representing the bottom third (slowest) and upper two-
thirds (medium/fast pace). We employed general linear models to
examine associations of walking speed with carotid IMT, making
the same adjustments as stated above. General linear models
were also employed to examine associations of walking speed
with metabolic risk markers, including BMI and body fat,
systolic blood pressure, total, HDL and LDL cholesterol, log-
transformed CRP and fasting glucose. All analyses were
conducted using SPSS version 15.
RESULTS
The sample consisted of 530 participants (284 men, 246 women,
mean6SD age 6366 years). Participants had moderately raised
cholesterol, but generally demonstrated low risk factors with low
rates of smoking and obesity and normal blood pressure (table 1).
None of the participants rated their health as ‘poor’, with 68% of
the sample giving ratings of ‘excellent’ or ‘very good’. The time
taken to complete the walking test ranged from 1.0 to 3.5 s and
the average coefﬁcient of variation between tests was 6.7%.
Faster walkers were slightly younger, more likely to come from
higher work grades, record higher scores on the SF-36 (better
physical function) and report better health (table 1). In addition,
faster walking speed was associated with lower adiposity, CRP
and LDL cholesterol after adjusting for age (see table 1). Blood
pressure levels and fasting glucose were unrelated to walking
speed. Participants who reported a usual walking pace of ‘brisk/
fast’ demonstrated faster walking times (age and sex-adjusted
mean difference  0.15, 95% CI  0.21 to  0.08 s) compared with
those reporting ‘slow/average’ walking pace. In addition,
participants with higher self-reported physical health (top third
of SF-36 scores) had marginally faster walking times (age and sex-
adjusted mean difference  0.07, 95% CI  0.15 to 0.01 s) than
those in the lowest third.
High levels of CAC (Agatston score $100) were detected in
24% of the sample. The association between self-reported and
objectively assessed walking pace is shown in table 2. Objectively
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Epidemiologyassessed (but not self-reported) faster walking speed was asso-
ciated with a lower risk of high CAC after adjustment for
potential confounders, OR 0.62 (95% CI 0.40 to 0.96) for the
fastest (upper two-thirds) versus slowest (bottom third) walkers.
Using linear analyses there was a marginal association between
the log-transformed Agatston score and continuous walking time
(age and sex adjusted b¼0.49, 95% CI  0.04 to 1.02), indicating
a greater extent of CAC in slower walkers. On average, there was
a difference of 0.16 s (95% CI 0.04 to 0.28) in the time to
complete the walking course in participants with no detectable
CAC compared with those with CAC of 400 or greater (see ﬁgure
1). Objectively assessed faster walking speed was also associated
with lower IMT (b¼ 0.034, 95% CI  0.002 to  0.067 mm) in
comparison with the slowest walkers (bottom third), after
adjusting for age, sex, social status, smoking, SF-36 and
conventional risk factors (ﬁgure 2). No sex differences were
observed in these associations (eg, p¼0.64 for sex interaction
with walking speed and CAC). High walking variability (top
third) was not a signiﬁcant predictor of CAC (age and sex
adjusted OR 1.28, 95% CI 0.76 to 2.18) or IMT (b¼ 0.008, 95%
CI  0.041 to 0.025 mm) in comparison with low walking vari-
ability (bottom third).
DISCUSSION
The present study examined the association of walking speed
with markers of subclinical atherosclerosis, assessed from both
CAC and carotid IMT, in a sample of older adults without overt
CVD. Faster pace walking speed assessed with a short-distance
test was associated with a lower prevalence and extent of CAC
and lower IMT values, independently of age and other CVD risk
factors. These associations were not observed when using the
self-reported measure of walking pace. In a recent analysis of the
full Whitehall II cohort that employed the short-distance test,
age-adjusted walking speed was approximately 13% higher in
the highest employment grade compared with the lowest,
13
although our ﬁndings suggest that associations with subclinical
atherosclerosis are independent of social status. We also observed
an association between walking speed and several markers of
metabolic health. Replicable ﬁndings across two independent
measures of preclinical atherosclerosis and consistent associa-
tions with atherosclerosis risk factors suggest that the associa-
tion between walking speed and preclinical atherosclerosis was
robust.
CAC has been shown to be independently predictive of CHD
risk over and above traditional cardiac risk factors,
2 and thus
may be important in the early detection of atherosclerosis. Our
ﬁndings extend those reported in the few previous smaller-scale
Table 1 Characteristics of the sample in relation to sex speciﬁc walking speed groups (mean6SD)
Variable All (n[530) Slowest (n[188) Medium (n[180) Fastest (n[162)
Age (years) 62.865.7 63.765.8 62.765.7 62.465.3y
Work grade (% lower grades) 24.2 26.1 24.4 15.4y
Marital status (% married) 63.5 62.6 68.0 62.7
Current smokers (%) 6.2 6.4 4.4 5.6
Alcohol (units/week) 9.068.6 9.869.9 9.269.2 8.367.5
Prescribed lipid-lowering medication (%) 2.4 3.2 3.3 0.6
SF-36 physical function score 82.8614.0 80.3615.0 84.0613.5z 84.3612.8z
Self-rated health (% fair) 4.7 6.4 5.0 2.5y
Moderate-vigorous activity (MET h/week)* 34.5629.6 32.6627.4 35.6626.4 35.6634.6
Systolic blood pressure (mm Hg) 123.2616.6 125.6617.1 122.8616.9 123.5614.9
Body mass index (kg/m
2) 25.664.1 26.264.1 25.763.6 25.663.9
Body fat % 30.868.3 31.460.4 30.760.4 30.160.4z
Total cholesterol (mmol/l) 5.8960.94 5.8860.97 5.9761.00 5.7261.01
HDL cholesterol (mmol/l) 1.7260.48 1.6860.47 1.7160.44 1.7160.50
LDL cholesterol (mmol/l) 3.9160.95 3.9560.93 4.0060.97 3.7660.94z
Log C-reactive protein 2.4460.14 2.4660.16 2.4360.13 2.4360.14z
Fasting glucose (mmol/l) 5.1860.51 5.1660.56 5.1860.49 5.2160.45
*Metabolic equivalents (MET) deﬁned from moderate (3e6 MET) to vigorous (>6 MET) physical activity.
ySigniﬁcant difference compared with slowest walkers.
zSigniﬁcant difference compared with slowest walkers in age-adjusted analyses.
HDL, high-density lipoprotein; LDL, low-density lipoprotein; SF-36, short-form 36.
Table 2 Logistic regression of objective and self-reported walking pace
on risk of CAC of 100 or greater
Walking
pace N
Model 1
OR (95% CI)
Model 2
OR (95% CI)
Model 3
OR (95% CI)
Objective
Slowest* 188 1.00 1.00 1.00
Brisk/fast 342 0.61 (0.40 to 0.92) 0.61 (0.40 to 0.94) 0.62 (0.40 to 0.96)
p Value 0.01 0.03 0.03
Self-reported
Slow/average 315 1.00 1.00 1.00
Brisk/fast 213 0.84 (0.54 to 1.31) 0.88 (0.56 to 1.39) 0.93 (0.58 to 1.50)
p Value 0.444 0.589 0.773
Model 1 adjusted for age and sex.
Model 2 with further adjustment for employment grade and smoking.
Model 3 with further adjustment for systolic blood pressure, low-density lipoprotein and
high-density lipoprotein cholesterol, C-reactive protein, fasting glucose, body mass index,
short-form 36 score, lipid-lowering medication.
*Slowest third consists of women with walking time greater than 2.10 s and men greater
than 1.94 s.
CAC, coronary artery calciﬁcation; OR, odds ratio.
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Figure 1 Time to complete walking test in relation to coronary artery
calcium scores. Values are mean6SEM, adjusted for age. White bars
represent men, ﬁlled bars represent women.
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Epidemiologystudies of objective walking speed and CAC. In community-
based samples of healthy elderly participants, walking speed over
a 15-ft course was inversely related to CAC in women but not
men,
4 and maximum walking pace was inversely associated with
carotid plaques and IMT.
5 Our ﬁndings are consistent with the
evidence that demonstrated associations of objective walking
speed with incident CVD and total mortality.
1 Other data have
shown an association between impaired physical performance
and inﬂammatory markers in the elderly.
14
Studies examining the association between self-reported
measures of physical activity and CAC have generally produced
inconsistent ﬁndings,
15e17 which may be explained by differ-
ences in physical activity assessment techniques between studies
and limitations of self-reported instruments. In a recent study
self-reported brisk walking pace was associated with lower CAC
and IMTin men but only IMTin women,
6 which contrasts with
our results that showed no associations.
MECHANISMS
As the study was cross-sectional, we cannot determine the
directionality of the association between walking speed and
preclinical atherosclerosis. Slow walking speed is related to lack
of physical exercise, which is a well-established CVD risk
factor,
18 and studies have demonstrated that physical inactivity
in mid-life can predict functional decline in older age.
19 There-
fore, the inverse association of walking speed and subclinical
atherosclerosis in older age may reﬂect cardioprotective effects of
physical ﬁtness and suggest that slow walking speed is an ante-
cedent to CVD rather than a consequence. Recent data have
conﬁrmed strong inverse associations of exercise capacity, chro-
notropic response and abnormal heart recovery during exercise
stress testing with CAC burden.
20 Given that our objective
measure of walking speed was closely associated with self-
reported usual walking pace, this might reﬂect a simple objective
measure of habitual physical activity and ﬁtness. Nevertheless,
self-reported walking pace in itself was not a robust predictor of
subclinical atherosclerosis. Controlled training studies in elderly
participants have demonstrated improvements in various meta-
bolic risk factors, including inﬂammatory markers and insulin
sensitivity.
21 22 However, experimental studies that examine the
effects of improved physical function on markers of subclinical
atherosclerosis are required.
Alternatively, subclinical vascular factors may play a role in
motor function, with slow walking speed reﬂecting functional
consequences of underlying long-term conditions not yet
apparent clinically. One hypothesis is that individuals with
preclinical atherosclerosis have increased cerebral white matter
hyperintensities, a condition that is associated with impaired
physical function, including slower gait speed.
23 24 This
hypothesis would imply an association between walking speed
and blood pressure, because hypertension, in addition to age, is
the main risk factor for white matter hyperintensities. However,
walking speed was not associated with systolic blood pressure
and was only marginally associated with self-reported physical
function in the present study. In addition, high walking vari-
ability has been associated with cognitive and functional status
and subclinical brain vascular abnormalities,
25 26 although
walking variability was not a predictor of subclinical athero-
sclerosis in the present study. Nevertheless, other important
mechanisms may also be involved. For example, cardiac abnor-
malities such as impaired left ventricular function that has been
associated with subclinical atherosclerosis,
27 may partly explain
reduced physical capacity.
28 Subclinical disease of the blood
vessels in the legs might lead to discomfort when walking, even
though claudication is not present, resulting in a slower pace.
Since the walking test is conducted from a standing start this
may be another important aspect that is not captured in walking
speed per se. This might partly explain the weak associations
with self-reported walking pace becausee it does not take into
account factors such as the initiation of movement.
CONCLUSION
The present ﬁndings have demonstrated the value of a simple
short-distance walking test in capturing the severity of
subclinical conditions in older adults not apparent in measures
of clinical CVD. We measured walking speed with an 8-ft test in
contrast to other studies that have generally employed longer
walking distances
1 or assessed maximal walking pace.
5 The main
difference in using a short-distance walking test is that it prob-
ably does not reﬂect aerobic capacity and the advantage is that it
requires little space and is safe and easy to administer. The short-
distance test is thus able to detect differences in subclinical
atherosclerosis and is also highly practical, making it a poten-
tially attractive measure for ofﬁce-based use in clinical practice.
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